Neuroprotective concentrations of the N-methyl-D-aspartate open-channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation
- PMID: 9697119
- DOI: 10.1016/s0306-4522(98)00163-8
Neuroprotective concentrations of the N-methyl-D-aspartate open-channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation
Abstract
The potential of most N-methyl-D-aspartate antagonists as neuroprotectants is limited by side effects. We previously reported that memantine is an open-channel N-methyl-D-aspartate blocker with a faster off-rate than many uncompetitive N-methyl-D-aspartate antagonists such as dizocilpine maleate. This parameter correlated with memantine's known clinical tolerability in humans with Parkinson's disease. Memantine is the only N-methyl-D-aspartate antagonist that has been used clinically for excitotoxic disorders at neuroprotective doses. Therefore, we wanted to investigate further the basis of its clinical efficacy, safety, and tolerability. Here we show for the first time for any clinically-tolerated N-methyl-D-aspartate antagonist that memantine significantly reduces infarct size when administered up to 2 h after induction of hypoxia/ischemia in immature and adult rats. We found that at neuroprotective concentrations memantine results in few adverse side effects. Compared to dizocilpine maleate, memantine displayed virtually no effects on Morris water maze performance or on neuronal vacuolation. At concentrations similar to those in brain following clinical administration, memantine (6-10 microM) did not attenuate long-term potentiation in hippocampal slices and substantially spared the N-methyl-D-aspartate component of excitatory postsynaptic currents, while dizocilpine maleate (6-10 microM) or D-2-amino-5-phosphovalerate (50 microM) completely blocked these phenomena. We suggest that the favorable kinetics of memantine interaction with N-methyl-D-aspartate channels may be partly responsible for its high index of therapeutic safety, and make memantine a candidate drug for use in many N-methyl-D-aspartate receptor-mediated human CNS disorders.
Similar articles
-
Effects of memantine and MK-801 on NMDA-induced currents in cultured neurones and on synaptic transmission and LTP in area CA1 of rat hippocampal slices.Br J Pharmacol. 1996 Feb;117(4):689-97. doi: 10.1111/j.1476-5381.1996.tb15245.x. Br J Pharmacol. 1996. PMID: 8646415 Free PMC article.
-
Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders.J Alzheimers Dis. 2004 Dec;6(6 Suppl):S61-74. doi: 10.3233/jad-2004-6s610. J Alzheimers Dis. 2004. PMID: 15665416
-
Neuroprotective properties of memantine in different in vitro and in vivo models of excitotoxicity.Eur J Neurosci. 2006 May;23(10):2611-22. doi: 10.1111/j.1460-9568.2006.04787.x. Eur J Neurosci. 2006. PMID: 16817864
-
The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism.Curr Alzheimer Res. 2005 Apr;2(2):155-65. doi: 10.2174/1567205053585846. Curr Alzheimer Res. 2005. PMID: 15974913 Review.
-
Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation.Curr Drug Targets. 2007 May;8(5):621-32. doi: 10.2174/138945007780618472. Curr Drug Targets. 2007. PMID: 17504105 Review.
Cited by
-
Mitochondrial calcium uniporter Mcu controls excitotoxicity and is transcriptionally repressed by neuroprotective nuclear calcium signals.Nat Commun. 2013;4:2034. doi: 10.1038/ncomms3034. Nat Commun. 2013. PMID: 23774321 Free PMC article.
-
Allograft of Sertoli Cell Transplantation in Combination with Memantine Alleviates Ischemia-Induced Tissue Damages in An Animal Model of Rat.Cell J. 2020 Oct;22(3):334-343. doi: 10.22074/cellj.2020.6689. Epub 2019 Dec 15. Cell J. 2020. PMID: 31863659 Free PMC article.
-
Developmental regulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor subunit expression in forebrain and relationship to regional susceptibility to hypoxic/ischemic injury. I. Rodent cerebral white matter and cortex.J Comp Neurol. 2006 Jul 1;497(1):42-60. doi: 10.1002/cne.20972. J Comp Neurol. 2006. PMID: 16680782 Free PMC article.
-
NMDA receptor blockade with memantine attenuates white matter injury in a rat model of periventricular leukomalacia.J Neurosci. 2008 Jun 25;28(26):6670-8. doi: 10.1523/JNEUROSCI.1702-08.2008. J Neurosci. 2008. PMID: 18579741 Free PMC article.
-
The dichotomy of memantine treatment for ischemic stroke: dose-dependent protective and detrimental effects.J Cereb Blood Flow Metab. 2015 Feb;35(2):230-9. doi: 10.1038/jcbfm.2014.188. Epub 2014 Nov 19. J Cereb Blood Flow Metab. 2015. PMID: 25407270 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources